Monopar Therapeutics Files 8-K
Ticker: MNPR · Form: 8-K · Filed: Jun 11, 2024 · CIK: 1645469
| Field | Detail |
|---|---|
| Company | Monopar Therapeutics (MNPR) |
| Form Type | 8-K |
| Filed Date | Jun 11, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: disclosure, financial-statements
TL;DR
Monopar Therapeutics filed an 8-K, check for new disclosures and financials.
AI Summary
Monopar Therapeutics Inc. filed an 8-K on June 11, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or details about new events, but serves as a notification of included exhibits and disclosures.
Why It Matters
This 8-K filing indicates that Monopar Therapeutics is providing updated disclosures and financial statements to the SEC, which could contain important information for investors.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for disclosures and exhibits, not indicating any immediate negative events.
Key Players & Entities
- Monopar Therapeutics Inc. (company) — Registrant
- June 11, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 1000 Skokie Blvd. , Suite 350 , Wilmette , IL 60091 (address) — Address of principal executive offices
- 847-388-0349 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing by Monopar Therapeutics?
The primary purpose of this 8-K filing is to report on Regulation FD Disclosure and Financial Statements and Exhibits.
On what date was the earliest event reported in this filing?
The earliest event reported in this filing was on June 11, 2024.
In which state was Monopar Therapeutics incorporated?
Monopar Therapeutics Inc. was incorporated in Delaware.
What is the principal executive office address for Monopar Therapeutics?
The principal executive office address is 1000 Skokie Blvd. , Suite 350 , Wilmette , IL 60091.
What is the telephone number for Monopar Therapeutics?
The telephone number for Monopar Therapeutics is (847) 388-0349.
Filing Stats: 435 words · 2 min read · ~1 pages · Grade level 10.2 · Accepted 2024-06-11 07:30:32
Key Financial Figures
- $0.001 — ge on which registered Common Stock , $0.001 par value MNPR The Nasdaq Stock Mar
Filing Documents
- mnpr20240610_8k.htm (8-K) — 25KB
- ex_686102.htm (EX-99.1) — 15KB
- monologo.jpg (GRAPHIC) — 4KB
- 0001437749-24-019881.txt ( ) — 185KB
- mnpr-20240611.xsd (EX-101.SCH) — 3KB
- mnpr-20240611_def.xml (EX-101.DEF) — 12KB
- mnpr-20240611_lab.xml (EX-101.LAB) — 16KB
- mnpr-20240611_pre.xml (EX-101.PRE) — 12KB
- mnpr20240610_8k_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On June 11, 2024, Monopar Therapeutics Inc. (Monopar) issued a press release announcing an amendment and expansion to their existing collaboration with NorthStar Medical Radioisotopes, LLC. The press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits Exhibit No. Description 99.1 Press Release Dated June 11, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Monopar Therapeutics Inc. Date: June 11, 2024 By: /s/ Kim R. Tsuchimoto Name: Kim R. Tsuchimoto Title: Chief Financial Officer and Director